TD Cowen initiated coverage of Astria Therapeutics with a Buy rating and $35 price target. The analyst cites the likelihood of STAR-0215 Phase III success and the company’s “significant potential” in hereditary angioedema prophylaxis for the Buy rating. The firm says consultant enthusiasm is high given Astria’s competitive efficacy, and they believe STAR-0215 has demonstrated dosing that meaningfully improves the administration burden and quality of life.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
Questions or Comments about the article? Write to editor@tipranks.com